Home
Press Releases
SEC Filings
Events
FAQs
Annual Reports
Fact Sheet
Management Team
Code of Ethics
Board of Directors
Stock Ownership
Contact Us

[2009 Archive] [2008 Archive] [2007 Archive] [2006 Archive] [2005 Archive] [2004 Archive] [2003 Archive] [2009_Archive]

Columbia Laboratories to Discuss First Quarter 2006 Financial Results

on May 9, 2006 Conference Call

LIVINGSTON, NJ – May 2, 2006 - Columbia Laboratories, Inc. (NASDAQ: CBRX) will hold a conference call on May 9, 2006 to review and discuss financial results of the first quarter which ended March 31, 2006. The call will be hosted by Robert Mills, Columbia’s president and chief executive officer, and David Weinberg, chief financial officer.

Access information

Date:  Tuesday, May 9, 2006
Time:  12:00 PM ET  
U.S./Canada dial-in number  (800) 811-8824
International dial-in number  (913) 981-4903
Participant passcode  2478266
Live webcast  www.columbialabs.com

Replay Access Information

A recording of the conference call will be available two hours after completion until May 16, 2006 at 11:59 PM ET at (888) 203-1112 (U.S.) and (719) 457-0820 (International). The replay password is 2478266. The webcast will be archived for on-demand listening for one year on Columbia Laboratories website, www.columbialabs.com.

About Columbia Laboratories, Inc.

Columbia Laboratories, Inc. is a U.S.-based international pharmaceutical company dedicated to the development and commercialization of women's health care and endocrinology products. Columbia markets Prochieve® 8% (progesterone gel) for progesterone supplementation as part of an Assisted Reproductive Technology treatment for infertile women with progesterone deficiency, and Prochieve® 4% (progesterone gel) for the treatment of secondary amenorrhea. The Company also markets Striant® (testosterone buccal system) for the treatment of hypogonadism in men. Columbia's products and product candidates utilize the Company's bioadhesive drug delivery technology, which is able to deliver a broad range of compounds, including peptides, across many of the body’s mucosal surfaces to address numerous therapeutic areas. The Company is investigating the potential utility of Prochieve® 8% in the prevention of preterm birth and developing a vaginally-administered lidocaine product to prevent and treat dysmenorrhea and pelvic pain. For more information, please visit www.columbialabs.com.

Striant® and Prochieve® are registered trademarks of Columbia Laboratories, Inc.

###